ES2570463T3 - Sulfonamidas para la prevención de la diabetes - Google Patents

Sulfonamidas para la prevención de la diabetes

Info

Publication number
ES2570463T3
ES2570463T3 ES10768898T ES10768898T ES2570463T3 ES 2570463 T3 ES2570463 T3 ES 2570463T3 ES 10768898 T ES10768898 T ES 10768898T ES 10768898 T ES10768898 T ES 10768898T ES 2570463 T3 ES2570463 T3 ES 2570463T3
Authority
ES
Spain
Prior art keywords
sulfonamides
diabetes prevention
diabetes
prevention
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10768898T
Other languages
English (en)
Spanish (es)
Inventor
Lorenzo Piemonti
Luisa Daffonchio
Marcello Allegretti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dompe Farmaceutici SpA
Original Assignee
Dompe Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Farmaceutici SpA filed Critical Dompe Farmaceutici SpA
Application granted granted Critical
Publication of ES2570463T3 publication Critical patent/ES2570463T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/51Y being a hydrogen or a carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES10768898T 2009-10-06 2010-10-06 Sulfonamidas para la prevención de la diabetes Active ES2570463T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09172365A EP2308485A1 (en) 2009-10-06 2009-10-06 Sulfonamides for the prevention of diabetes
PCT/EP2010/064920 WO2011042465A1 (en) 2009-10-06 2010-10-06 Sulfonamides for the prevention of diabetes

Publications (1)

Publication Number Publication Date
ES2570463T3 true ES2570463T3 (es) 2016-05-18

Family

ID=41716341

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10768898T Active ES2570463T3 (es) 2009-10-06 2010-10-06 Sulfonamidas para la prevención de la diabetes

Country Status (24)

Country Link
US (2) US8846755B2 (enExample)
EP (2) EP2308485A1 (enExample)
JP (1) JP5745526B2 (enExample)
KR (1) KR101737656B1 (enExample)
CN (1) CN102639128B (enExample)
AU (1) AU2010305384B2 (enExample)
BR (1) BR112012007989B1 (enExample)
CA (1) CA2776021C (enExample)
CY (1) CY1117599T1 (enExample)
DK (1) DK2485724T3 (enExample)
EA (1) EA021788B1 (enExample)
ES (1) ES2570463T3 (enExample)
HR (1) HRP20160399T1 (enExample)
HU (1) HUE028132T2 (enExample)
IL (1) IL219038A (enExample)
ME (1) ME02385B (enExample)
MX (1) MX2012004087A (enExample)
NZ (1) NZ599171A (enExample)
PL (1) PL2485724T3 (enExample)
RS (1) RS54693B1 (enExample)
SI (1) SI2485724T1 (enExample)
SM (1) SMT201600126B (enExample)
WO (1) WO2011042465A1 (enExample)
ZA (1) ZA201202462B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN109890364B (zh) 2016-10-03 2023-10-17 儿童医疗中心公司 糖尿病肾病的预防和治疗

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
ITMI20010206A1 (it) 2001-02-02 2002-08-02 Dompe Spa Uso della metansolfonammide di (r)-ibuprofene e dei suoi sali non tossici per la preparazione di medicamenti per il trattamento e la prevenz
US20040242498A1 (en) * 2003-02-27 2004-12-02 Collins Tassie L. CXCR3 antagonists
PT1776336E (pt) 2004-03-23 2009-12-18 Dompe Spa Derivados de ácido 2-fenilpropiónico e composições farmacêuticas que os contêm
EP1579859B1 (en) 2004-03-25 2006-12-13 DOMPE' pha.r.ma s.p.a. Use of N-(2-aryl-propionyl)-sulfonamides for the treatment of spinal cord injury
WO2009117706A2 (en) * 2008-03-20 2009-09-24 Carolus Therapeutics, Inc. Methods of treatment using anti-mif antibodies
EP2308485A1 (en) 2009-10-06 2011-04-13 Dompé S.p.a. Sulfonamides for the prevention of diabetes
EP2308484A1 (en) * 2009-10-06 2011-04-13 Dompé S.p.a. Inhibitors of cxcr1/2 as adjuvants in the transplant of pancreatic islets

Also Published As

Publication number Publication date
KR101737656B1 (ko) 2017-05-18
EP2485724B1 (en) 2016-02-10
SMT201600126B (it) 2016-07-01
US9556115B2 (en) 2017-01-31
US20130059908A1 (en) 2013-03-07
NZ599171A (en) 2014-03-28
HUE028132T2 (en) 2016-11-28
BR112012007989B1 (pt) 2019-10-22
US8846755B2 (en) 2014-09-30
EA021788B1 (ru) 2015-08-31
US20150011639A1 (en) 2015-01-08
AU2010305384A1 (en) 2012-04-26
DK2485724T3 (en) 2016-05-02
ZA201202462B (en) 2013-06-26
CA2776021A1 (en) 2011-04-14
ME02385B (me) 2016-09-20
WO2011042465A1 (en) 2011-04-14
CA2776021C (en) 2017-08-01
CN102639128A (zh) 2012-08-15
EA201270512A1 (ru) 2012-11-30
RS54693B1 (sr) 2016-08-31
CY1117599T1 (el) 2017-04-26
EP2308485A1 (en) 2011-04-13
IL219038A0 (en) 2012-06-28
CN102639128B (zh) 2014-02-26
EP2485724A1 (en) 2012-08-15
PL2485724T3 (pl) 2016-07-29
HK1174557A1 (en) 2013-06-14
SI2485724T1 (sl) 2018-12-31
KR20120083889A (ko) 2012-07-26
JP5745526B2 (ja) 2015-07-08
JP2013506703A (ja) 2013-02-28
AU2010305384B2 (en) 2016-02-04
IL219038A (en) 2015-07-30
MX2012004087A (es) 2012-08-23
HRP20160399T1 (hr) 2016-05-20

Similar Documents

Publication Publication Date Title
UY32490A (es) Inhibidores de beta-secretasa
EA201270216A1 (ru) Фармацевтический состав
CL2008003690A1 (es) Compuestos derivados de amonobenzamida; composicion farmceutica que comprende los compuestos; y uso para controlar parasitos.
CO6430459A2 (es) Derivados de prolina como inhibidores de catepsina
SV2010003472A (es) Compuestos de pirazol
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
CO6620055A2 (es) Ciertas amino-pirimidinas, composiciones de las mismas y métodos para el uso de los mismos
NO20091395L (no) Nye tiofenderivater
NO20091553L (no) Fenylderivater og deres anvendelse som immunmodulatorer
AR082600A1 (es) Polimorfos cristalinos de la sal de besilato de n-(3-(5-fluor-2-(4-(2-metoxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida, composiciones farmaceuticas que los contienen y uso de los mismos para tratar canceres, enfermedades autoinmunes y oseas, entre otras
CR20110370A (es) Derivados de sulfonamida
CL2011000242A1 (es) Uso de compuestos derivados de fenilaminopirimidina para tratar talasemia alfa, delta y anemia celular falciforme, talasemia mayor, talasemia menor, talasemia e-beta o talasemia beta falciforme, o para mejorar o retrasar los sintomas de las mismas y uso de un compuesto especifico para tratar la talasemia.
DOP2012000006A (es) Agonista de gpr119
BR112015007310A2 (pt) compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica
EA201190320A1 (ru) Гетероциклические сульфонамиды, их применения и фармацевтические композиции
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
AR083417A1 (es) Composiciones farmaceuticas que contienen un dgat1 inhibidor
CL2012002716A1 (es) Uso de un compuesto inhibidores de dgat1 porque es útil en la prevención, demora del progreso o el tratamiento de una enfermedad o condición seleccionada a partir de quilomicronemia, síndrome de quilomicronemia familiar e hiperlipoproteinemia tipo v; un compuesto derivado de heteroarilo sustituido; composición farmacéutica.
BRPI0916480A2 (pt) composto de fórmula geral (i) e uso de pelo menos um composto
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
BRPI0924882A2 (pt) Composição para cuidado oral, e, uso de pelo menos um composto de carbonato e pelo menos um excipiente
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
EA201290229A1 (ru) Производные спиролактама и их применение
UY32408A (es) Macrolido anti-inflamatorio